- Home
- WLK vs MRNA Comparison
WLK vs MRNA Comparison
Compare WLK & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLK | MRNA |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 9.3B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WLK | MRNA |
|---|---|---|
| Price | $67.75 | $27.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | ★ $88.00 | $33.91 |
| AVG Volume (30 Days) | 1.6M | ★ 9.9M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,480,000,000.00 | $2,232,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.18 | $0.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $56.33 | $22.28 |
| 52 Week High | $128.85 | $48.92 |
Technical Indicators
Market Signals| Indicator | WLK | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 60.85 |
| Support Level | $56.33 | $23.92 |
| Resistance Level | $70.31 | $26.00 |
| Average True Range (ATR) | 2.88 | 1.29 |
| MACD | 1.42 | 0.32 |
| Stochastic Oscillator | 83.23 | 99.82 |
Price Performance
Historical ComparisonAbout WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.